AAIC 2025 Abstract·25 DecMultiple‐Dose Results from an Ongoing Phase 1 Study of Mivelsiran, an Investigational RNA Interference Therapeutic Targeting Amyloid‐Beta Precursor Protein for Alzheimer’s DiseaseTrial in peopleInterventionsPaper